Understanding how doctors identify NTRK gene fusion overexpression is crucial for patients who may benefit from specialized treatment options. When a piece of a chromosome carrying an NTRK gene breaks apart and joins with another gene, it creates an abnormal fusion that can drive cancer growth. Finding this change through proper testing can open doors to targeted therapies that might not be available through standard cancer tests.

Who Should Consider NTRK Fusion Testing

Anyone diagnosed with cancer may potentially harbor an NTRK gene fusion, which occurs when part of an NTRK gene mistakenly connects to an unrelated gene. This creates an abnormal instruction manual that tells cells to grow uncontrollably. While this change is found in fewer than one out of every 100 cancers overall, certain rare tumor types show this fusion much more frequently.^[1]

Testing becomes especially important for people diagnosed with specific rare cancers where NTRK fusions appear in more than 80 percent of cases. These include infantile fibrosarcoma in young children, secretory breast carcinoma, and mammary analog secretory carcinoma of the salivary gland. For these patients, identifying the fusion is almost expected and should be part of routine diagnostic workup.^[13]

However, NTRK fusions also occur in smaller numbers across many common cancer types. People with non-small cell lung cancer, colorectal cancer, sarcoma, thyroid cancer, brain tumors, and various other solid tumors may carry this fusion even when their cancer appears typical.^[1][11] The challenge is that these patients might never be tested because doctors often don’t think to look for such rare changes.

Patients whose cancers have progressed despite standard treatments should strongly consider comprehensive testing that includes NTRK fusion detection. When conventional therapies stop working, finding a targetable fusion like NTRK can provide new treatment pathways. This is particularly valuable for people with advanced or metastatic disease who need additional options beyond chemotherapy.^[8]

Children with cancer deserve special consideration for NTRK fusion testing. Certain childhood cancers show higher rates of these fusions, and targeted treatments have demonstrated remarkable effectiveness in young patients. Since these therapies generally cause fewer side effects than traditional chemotherapy, identifying eligible children becomes even more important for their quality of life during treatment.^[10]

It is advisable to seek testing when diagnosed with a cancer type known to occasionally harbor NTRK fusions, when cancer spreads despite treatment, or when enrolled in a facility that offers comprehensive molecular profiling. Economic considerations and access to testing facilities may influence when and how testing occurs, but the potential to discover a treatable fusion makes the effort worthwhile for many patients.^[3]

Standard Diagnostic Methods for Detecting NTRK Fusions

Several laboratory techniques can detect NTRK gene fusions, each with distinct strengths and limitations. Understanding these methods helps patients comprehend what their doctors are looking for and why certain tests might be recommended over others. The choice of testing method often depends on what is available at a particular medical facility, the cost, and how much tumor tissue is available for analysis.^[3]

Immunohistochemistry Testing

Immunohistochemistry, often abbreviated as IHC, is typically the first screening test used to look for NTRK fusions. This method examines thin slices of tumor tissue under a microscope after applying special antibodies that stick to TRK proteins. When NTRK fusion occurs, cells often produce abnormally large amounts of TRK protein, which the antibodies can detect by creating a visible color change in the tissue.^[3]

The main advantage of IHC testing is that it is relatively inexpensive and widely available at most pathology laboratories. Results typically come back within a few days, making it a practical first step. However, IHC has important limitations. It can sometimes show positive results even when no actual gene fusion exists, because some tumors naturally produce high levels of TRK protein for other reasons. This means a positive IHC result must always be confirmed with additional testing to verify that a true fusion is present.^[3]

Conversely, IHC may occasionally miss real fusions if the tumor doesn’t produce enough protein to be detected. Despite these limitations, IHC serves as a useful and cost-effective screening tool. When IHC shows a possible fusion, doctors move on to more definitive testing methods to confirm the finding.^[5]

Fluorescence In Situ Hybridization

Fluorescence in situ hybridization, known as FISH, uses fluorescent probes that attach to specific genes on chromosomes. When viewed under a special microscope, these probes light up in different colors. If an NTRK gene has broken apart and fused with another gene, the normal pattern of fluorescent signals appears disrupted, revealing the rearrangement.^[3]

FISH testing provides direct visual evidence of gene rearrangement and can confirm whether chromosome breaks have occurred in the NTRK region. This makes it more reliable than IHC for verifying fusions. However, FISH requires specific probes designed for each of the three NTRK genes, and it cannot identify what partner gene has joined with NTRK. Knowing the partner gene can sometimes matter for understanding how the cancer behaves or for selecting specific treatments.^[5]

Additionally, FISH testing demands high-quality tumor tissue and specialized equipment that may not be available at all facilities. The technique works best when doctors already suspect an NTRK fusion based on previous screening tests. While FISH confirms that rearrangement has occurred, it doesn’t provide the complete genetic details that some newer testing methods can reveal.^[3]

DNA-Based Next-Generation Sequencing

Next-generation sequencing, abbreviated as NGS, represents a more comprehensive approach that analyzes many genes simultaneously. DNA-based NGS reads through the genetic code of tumor cells looking for various mutations, including gene fusions. This method can examine dozens or even hundreds of cancer-related genes in a single test, providing a complete picture of a tumor’s genetic makeup.^[3]

The strength of DNA-based NGS lies in its ability to identify not only NTRK fusions but also other potentially targetable genetic changes. For patients whose tumors lack NTRK fusions, the same test might reveal different abnormalities that could guide treatment decisions. This comprehensive approach maximizes the value of limited tumor tissue, which is especially important when biopsies yield small samples.^[13]

However, DNA-based NGS has a significant limitation when it comes to detecting gene fusions. While it excels at finding point mutations—single letter changes in the genetic code—it sometimes struggles to identify complex rearrangements where large pieces of chromosomes swap positions. Depending on how the sequencing is performed and analyzed, some fusions may be missed, particularly if the breakpoints occur in unusual locations.^[3]

RNA-Based Next-Generation Sequencing

RNA-based NGS offers the most reliable method for detecting NTRK gene fusions. Instead of reading the DNA instruction manual itself, this technique examines RNA, which is the active copy that cells make when they actually use genes. When a fusion gene exists, cells create fusion RNA that combines sequences from both partner genes, and RNA-based sequencing can detect this abnormal combination very effectively.^[3]

This approach identifies both the NTRK gene involved and its partner gene, providing complete information about the fusion. It can detect fusions regardless of where the chromosome break occurred or how complex the rearrangement might be. RNA-based NGS also tends to be more sensitive than DNA-based methods, meaning it can find fusions even when they’re present in only a portion of tumor cells.^[3]

The main drawback of RNA-based sequencing is that it requires very well-preserved tumor tissue. RNA molecules are fragile and break down quickly after tissue is removed from the body. If tumor samples are old or were not handled properly, the RNA may be too degraded for accurate testing. Additionally, RNA sequencing is generally more expensive than other methods and may not be available at all testing facilities.^[14]

Reverse Transcriptase-Polymerase Chain Reaction

Reverse transcriptase-polymerase chain reaction, called RT-PCR, is another RNA-based method that specifically looks for known fusion combinations. This technique makes many copies of genetic material from suspected fusions, amplifying them enough to be easily detected. RT-PCR works well when doctors know which specific fusions to look for based on the type of cancer being tested.^[5]

RT-PCR can be highly sensitive and specific when targeting known fusion partners. However, it requires designing specific tests for each possible fusion combination. Since NTRK genes can fuse with dozens of different partner genes, RT-PCR cannot serve as a universal screening tool. It works best for cancers where certain fusion partners commonly occur, such as ETV6-NTRK3 fusion in congenital fibrosarcoma.^[5]

Liquid Biopsy and Circulating Tumor DNA

Blood-based testing, often called liquid biopsy, represents an emerging approach that analyzes fragments of tumor DNA floating in the bloodstream. When cancer cells die, they release their DNA into the blood, where specialized tests can detect it. This circulating tumor DNA, or ctDNA, may contain NTRK fusions if they’re present in the cancer.^[4]

Liquid biopsy offers significant advantages because it only requires a blood draw rather than a tissue biopsy. This makes testing less invasive and allows repeated sampling to monitor how cancers change over time. Patients who cannot safely undergo tissue biopsy due to tumor location or health status may still access testing through blood samples.^[14]

However, liquid biopsy has important limitations for detecting NTRK fusions. The amount of tumor DNA in blood varies greatly between patients and tumor types. Some cancers shed very little DNA into circulation, making them difficult or impossible to detect through blood testing. Additionally, liquid biopsy may miss fusions that tissue testing would find. In at least one documented case, tissue testing revealed an NTRK fusion that was completely absent in the patient’s blood test performed around the same time.^[4]

Testing Approaches for Clinical Trial Enrollment

When patients consider joining clinical trials studying NTRK fusion-positive cancers or testing new treatments, the diagnostic requirements often become more stringent than those used in routine clinical care. Clinical trials need highly accurate and reproducible test results to ensure that enrolled patients truly have the genetic changes being studied. Understanding these requirements helps patients prepare for the testing process and know what to expect.^[8]

Most clinical trials investigating treatments for NTRK fusion-positive cancers require definitive confirmation of the fusion through next-generation sequencing. While immunohistochemistry might serve as an initial screening tool in clinical practice, trials typically demand NGS confirmation because this method provides the most detailed information about the specific fusion present. The testing must identify which NTRK gene is involved (NTRK1, NTRK2, or NTRK3) and which partner gene has fused with it.^[8]

Trial sponsors often specify which testing platforms or laboratories are acceptable for confirming NTRK fusion status. Some studies require that testing be performed at designated central laboratories that have been validated for the specific trial. This ensures standardization across all participants and eliminates variability that might come from different testing facilities using different methods or interpreting results differently.^[6]

The quality and quantity of tumor tissue submitted for testing matters greatly in the trial setting. Clinical trials typically require that tumor samples meet minimum standards for tumor cell percentage—meaning that enough actual cancer cells must be present in the biopsy relative to normal tissue. If a biopsy contains mostly normal cells with just a few scattered tumor cells, the genetic signal from the fusion may be too weak to detect reliably. Fresh biopsies often provide better quality material than archived tissue that has been stored for months or years.^[3]

Some trials studying drugs that target NTRK fusions include patients who are “TRK inhibitor naive,” meaning they have never received treatment specifically targeting the fusion. These studies may require documentation that previous treatments did not include TRK inhibitors and may even require testing to confirm that the tumor hasn’t developed resistance mutations. This ensures that observed responses truly reflect the drug’s activity against treatment-naive NTRK fusions.^[8]

Clinical trials may also mandate additional testing beyond NTRK fusion detection to characterize the tumor more completely. This can include evaluating other genetic mutations, measuring tumor mutational burden (how many mutations exist throughout the cancer’s genome), or assessing markers related to immune system activity. These additional tests help researchers understand not only whether patients respond to treatment, but also why some respond better than others.^[13]

The timing of testing relative to trial enrollment can be critical. Some studies accept test results performed months or even years before enrollment, while others require fresh testing shortly before patients begin treatment. When cancers progress or receive intervening therapies, their genetic makeup can change. A fusion present at initial diagnosis might no longer drive the cancer’s growth after multiple treatment lines, or new resistance mechanisms might have emerged.^[11]

For patients whose initial diagnostic testing didn’t include comprehensive NTRK fusion analysis, clinical trials may arrange and cover the cost of appropriate testing as part of screening procedures. This allows patients who wouldn’t otherwise have access to expensive sequencing tests to determine their eligibility. However, this screening process can take several weeks, which may be challenging for patients with rapidly progressing disease who need to start treatment quickly.^[10]

Documentation requirements for clinical trial enrollment extend beyond just the test result itself. Trials typically need the full pathology report describing the tumor type and characteristics, the detailed testing report showing exactly which fusion was detected and what methodology was used, and confirmation that the sample tested actually came from the patient being enrolled. This paperwork trail, while sometimes tedious, protects both patients and researchers by ensuring accuracy.^[6]

Some specialized trials focus specifically on rare fusion partners or unusual fusion configurations. These studies might exclude patients with common fusion combinations that have already been well studied, instead seeking to understand how different fusion partners affect treatment response. Such trials require very detailed characterization of the fusion, often demanding RNA sequencing data that precisely maps where the break and fusion occurred.^[13]